Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BB-TL1A-VIAL-HLE in healthy volunteers and ulcerative colitis
NCT07029971Phase 1Terminated
- Sponsor
- Vial
- Start
- Jun 2025
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of BB-TL1A in ulcerative colitis (UC) (5 cohorts), sponsored by Vial. Primary endpoints: Dose Limiting or Intolerable Treatment Related Adverse Events at 355 days, Treatment Emergent Adverse Events at 355 days and 3 more. Started Jun 2025; status: terminated.
02
Drugs
BB-TL1A
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07029971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07029971.